scholarly journals Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status

2014 ◽  
Vol 16 (6) ◽  
pp. 779-786 ◽  
Author(s):  
Anne L. Baldock ◽  
Kevin Yagle ◽  
Donald E. Born ◽  
Sunyoung Ahn ◽  
Andrew D. Trister ◽  
...  
2019 ◽  
Vol 18 ◽  
pp. 153601211989408
Author(s):  
Nijiati Kudulaiti ◽  
Huiwei Zhang ◽  
Tianming Qiu ◽  
Junfeng Lu ◽  
Abudumijiti Aibaidula ◽  
...  

Purpose: We evaluated the relationship between isocitrate dehydrogenase 1 (IDH1) mutation status and metabolic imaging in patients with nonenhancing supratentorial diffuse gliomas using 11C-methionine positron emission tomography (11C-MET PET). Materials and Methods: Between June 2012 and November 2017, we enrolled 86 (38 women and 48 men; mean age, 41.9 ± 13.1 years [range, 8-67 years]) patients with newly diagnosed supratentorial diffuse gliomas. All patients underwent preoperative 11C-MET PET. Tumor samples were obtained and immunohistochemically analyzed for IDH1 mutation status. Results: The mutant and wild-type IDH1 diffuse gliomas had significantly different mean maximum standardized uptake value values (2.73 [95% confidence interval, CI: 2.32-3.16] vs 3.85 [95% CI: 3.22-4.51], respectively; P = .004) and mean tumor-to-background ratio (1.90 [95% CI: 1.65-2.16] vs 2.59 [95% CI: 2.17-3.04], respectively; P = .007). Conclusions: 11C-methionine PET can noninvasively evaluate the IDH1 mutation status of patients with nonenhancing supratentorial diffuse gliomas.


2018 ◽  
Vol 47 ◽  
pp. 168-173 ◽  
Author(s):  
Arian Lasocki ◽  
Frank Gaillard ◽  
Mark Tacey ◽  
Katharine Drummond ◽  
Stephen Stuckey

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 2026-2026
Author(s):  
Mariko Sato ◽  
Kenneth D. Aldape ◽  
Clinton C Mason ◽  
Kristin Diefes ◽  
Lindsey Heathcock ◽  
...  

2026 Background: The genetic alterations of glioma have been studied extensively. IDH1 mutation is associated with younger age and better survival. However, differences in molecular ontogeny within glioma related to IDH1 mutation remain unknown. Here we describe a detailed analysis of copy number alterations (CNA) between IDH1mut vs IDH1wt gliomas of grade 2-3 and 4. Methods: CNA were detected by molecular inversion probes (Affymetrix) and analyzed with Nexus Copy Number Software (BioDiscovery). DNA was extracted from 94 patient FFPE samples including grade 2-3: IDH1wt (n = 17) and IDH1mut (n = 28), and grade IV: IDH1wt ( n = 25) and IDH1mut(n = 24). Chromothripsis was detected using a stringent criteria of at least ten switches of CNA in individual chromosomes. Results: We validated prior findings that IDH1wt GBM have higher frequency of Chr7 amplification (including EGFR) and loss of Chr10 (including PTEN). Other CNA across all grades were: gain of 19q12 and loss of 14q11 in IDH1wt, and gain of 11q21, 10p11, 8q21 and loss of 11p15, 19q13 in IDH1mut. Within grade 2-3 samples, few CNA were associated with mutation status: 2-3wt demonstrated higher frequencies of gain of 7q and loss of 10q, 14q11, and 22q13, while 2-3mut demonstrated higher frequencies of 11q21 gain and 19q13 loss. Grade 4 tumors demonstrated more CNA that differed by mutation status, with 4wt tumors demonstrating gain of 7 and loss of 10 and 14q11, while 4mut demonstrated gains of 8q, 10p, 12p13, 1q23, and loss of 11p15, 3p, 19q13, among others. Comparison of grade 2-3mut vs grade 4mut tumors demonstrated larger number of CNA in the grade 4mut tumors including gain of 1p, 14q, 13q33, 9p, 8q and loss of 22q, 11p15, 10q, and 3p, among others. A significantly higher incidence of chromothripsis events was observed in grade 4mut compared to grade 4wt (p = 0.0374). Conclusions: CNA analysis showed significant differences in molecular ontogeny between IDH1wt and IDH1mut, some of which may further elucidate pathogenesis. Significant CNA increases and increased chromthripsis in grade 4mut support malignant transformation of low grade gliomas through accumulation of genomic instability and genomic catastrophe.


2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 2073-2073 ◽  
Author(s):  
Jacob Joseph Mandel ◽  
David Cachia ◽  
Diane D Liu ◽  
Kenneth D. Aldape ◽  
Greg Fuller ◽  
...  

PLoS ONE ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. e0199379 ◽  
Author(s):  
Paul Blanc-Durand ◽  
Axel Van Der Gucht ◽  
Antoine Verger ◽  
Karl-Josef Langen ◽  
Vincent Dunet ◽  
...  

Neurosurgery ◽  
2020 ◽  
Vol 87 (4) ◽  
pp. E513-E519 ◽  
Author(s):  
Marc Barritault ◽  
Thiébaud Picart ◽  
Delphine Poncet ◽  
Tanguy Fenouil ◽  
Anne d’Hombres ◽  
...  

Abstract BACKGROUND Biopsies in patients with a suspected glioma are occasionally nondiagnostic. OBJECTIVE To explore the utility of molecular testing in this setting by determining whether IDH1 and TERT promoter (pTERT) mutations could be detected in nondiagnostic biopsies from glioma patients. METHODS Using SNaPshot polymerase chain reaction, we retrospectively assessed IDH1 and pTERT mutation status in nondiagnostic biopsies from 28 glioma patients. RESULTS The nondiagnostic biopsy (needle biopsy n = 25, open or endoscopic biopsy n = 3) consisted of slight glial cell hypercellularity, hemorrhage, and/or necrosis. After another biopsy (n = 23) or a subsequent surgical resection (n = 5) the diagnosis was an IDH1-wildtype (WT) pTERT-mutant glioma (glioblastoma n = 16, astrocytoma n = 4), an IDH1-mutant pTERT-mutant oligodendroglioma (n = 1), an IDH1-mutant pTERT-WT astrocytoma (n = 1), and an IDH1-WT pTERT-WT glioblastoma (n = 6). An IDH1 mutation was identified in the nondiagnostic biopsies of the 2 IDH-mutant gliomas, and a pTERT mutation in the nondiagnostic biopsies of 16 out of the 21 of pTERT mutant-gliomas (76%). Overall, an IDH1 and/or a pTERT mutation were detected in 17 out of 28 (61%) of nondiagnostic biopsies. Retrospective analysis of the nondiagnostic biopsies based on these results and on imaging characteristics suggested that a new biopsy could have been avoided in 6 patients in whom a diagnosis of “molecular glioblastoma” could have been done with a high level of confidence. CONCLUSION In the present series, IDH1 and pTERT mutations could be detected in a high proportion of nondiagnostic biopsies from glioma patients. Molecular testing may facilitate the interpretation of nondiagnostic biopsies in patients with a suspected glioma.


2014 ◽  
Vol 16 (suppl 5) ◽  
pp. v29-v29
Author(s):  
O. Uckermann ◽  
T. Juratli ◽  
M. Conde ◽  
R. Galli ◽  
D. Krex ◽  
...  

2018 ◽  
Vol 7 (12) ◽  
pp. 5999-6009 ◽  
Author(s):  
Zhi-Cheng Li ◽  
Hongmin Bai ◽  
Qiuchang Sun ◽  
Yuanshen Zhao ◽  
Yanchun Lv ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document